Other valvular and structural interventions

Find all the latest content on other valvular and structural interventions published on this website.

Understanding and treating complications that might arise in valvular and structural interventions such as paravalvular leak after implantation of prosthetic valves is important. Information on determining the scope of this complication, it’s potential closure, along with other critical topics in this field can be found in this section.

Filtered By
Other valvular and structural interventions

55 results

SPOTLIGHT: Standardised definitions for clinical and imaging endpoints after surgical and transcatheter valve intervention

In this presentation from PCR London Valves 2017, A. Baumbach, D. Capodanno, A. Lansky, M.B. Leon and N. Piazza focus on the durability, structural deterioration and valve failure, the neurological adverse events and on what really matters in clinical and patient-reported endpoints after surgical and transcatheter valve interventions.

Transcatheter heart valve therapies for all heart valves

24 Sep 2017 - From PCR LONDON VALVES 2017

Chairpersons: M.B. Leon , S. Windecker

Objectives: To learn about the Edwards Lifesciences innovation pipeline for the aortic, mitral, tricuspid and pulmonary valve, to understand the latest and upcoming evidence in the aortic field, to learn about the economic value of innovative technology

Highlights of the Course PCR London Valves 2017

We offer our heartfelt thanks to the 2.576 active participants who made this 2017 edition of PCR London Valves a resounding success! What, you weren't there? Don't worry, we'll be back next year with even more challenge, more innovations, and more of you! Until then, why don't you take a walk with us through the highlights of PCR London Valves 2017? 19 Industry Partners, 303 participants at Innovators Day London, more than 240 submissions... See you next year!

Keynote lecture - Valve surgery and valve surgeons: past, present and future

26 Sep 2017 – From PCR London Valves 2017

Consult this session on the Keynote lecture from PCR London Valves 2017 on valve surgery and valve surgeons: past, present and future. O. Alfieri, F. Maisano and S. Windecker focus on the developments in valvular interventions.

Changing the paradigm in valvular heart disease - Beyond guidelines

Speakers: S. Berti, G. Brueren, P. MacCarthy, W. Woan

Learning objectives: To focus on patients and their access to treatments, reflect on the disparity in therapy adoption throughout EU, learn how to improve diagnosis and referral rates.

The new ESC guidelines for valvular heart disease

26 Sep 2017 – From PCR London Valves 2017

Consult this session from PCR London Valves 2017 on the 2017 ESC Guidelines on Valvular Heart Disease if you want to find out more about implementing the guidelines in daily clinical practice, where do we need more evidence and more...

World Heart Day 2017: 29 September

Born in 2000, World Heart Day is an initiative of the World Heart Federation. All over the World – in nearly 100 countries - member organisations will set up thousands of educational activities and events in order everyone feels involved in protecting themselves from cardiovascular disease, the leading cause of death worldwide killing 17.5 million a year.

Keynote lecture - Multiple valve disease: challenges in diagnosis, assessment and treatment

25 Sep 2017 – From PCR London Valves 2017

Consult the Keynote lecture from PCR London Valves 2017 on multiple valve disease: challenges in diagnosis, assessment and treatment. J. Bax, J. Fajadet and A. Vahanian shares their expertise on the subject.

Transcatheter heart valve therapies for all heart valves: from an innovation strategy to mainstream therapy

24 Sep 2017 – From PCR London Valves 2017

New ESC/EACTS Guidelines for the management of Valvular Heart Disease (VHD)

31 Aug 2017

The new joint ESC/EACTS guidelines for the management of valvular heart disease have been hotly anticipated, with extended indications for transcutaneous aortic valve implantation (TAVI) widely tipped to be the star of the show. In comparison to 2012, where data from two randomized control trials assessing TAVI were available, outcome data from nearly six thousand patients across six randomized trials were available to the 2017 guideline writing committee. Therefore, the major challenge for this guideline was to assimilate this data and make it applicable in realworld clinical practice. In that regard, this new document has evolved beyond simple ‘guidance’ and now introduces new ‘concepts of care’ for patients with valvular heart disease.

Christopher Cook

Author

Christopher Cook